DnB Asset Management
VKTX icon

DnB Asset Management’s Viking Therapeutics VKTX Stock Holding History

DnB Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$778K Sell
19,942
-4,129
-17% -$133K ﹤0.01% 674
2026
Q1 		$783K Sell
24,071
-3,305
-12% -$106K ﹤0.01% 670
2025
Q4 		$963K Buy
27,376
+4,655
+20% +$165K ﹤0.01% 639
2025
Q3 		$597K Buy
22,721
+1,853
+9% +$55.3K ﹤0.01% 664
2025
Q2 		$553K Buy
20,868
+1,373
+7% +$36.1K ﹤0.01% 644
2025
Q1 		$471K Sell
19,495
-11,171
-36% -$353K ﹤0.01% 660
2024
Q4 		$1.23M Buy
30,666
+15,209
+98% +$867K 0.01% 630
2024
Q3 		$979K Buy
15,457
+6,303
+69% +$370K ﹤0.01% 631
2024
Q2 		$485K Buy
9,154
+1,725
+23% +$113K ﹤0.01% 655
2024
Q1 		$609K Buy
+7,429
New +$331K ﹤0.01% 642

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DnB Asset Management's VKTX Position: Q2 2026 in Review

DnB Asset Management reduced its Viking Therapeutics (VKTX) stake by 17% in Q2 2026, selling an estimated $133K and leaving 19,942 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #674.

DnB Asset Management first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.23M in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • DnB Asset Management held 19,942 shares of Viking Therapeutics worth $778K as of Q2 2026.
  • DnB Asset Management sold 4,129 Viking Therapeutics shares in Q2 2026, an estimated $133K.
  • Viking Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #674 holding.
  • DnB Asset Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • DnB Asset Management's Viking Therapeutics position peaked at $1.23M in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.